BAXTER INVESTS $20 MIL. IN TRANSPLANT TECHNOLOGY PARTNERSHIP WITH DNX
This article was originally published in The Gray Sheet
Executive SummaryBAXTER INVESTS $20 MIL. IN TRANSPLANT TECHNOLOGY PARTNERSHIP WITH DNX, according to the companies. The new entity, Nextran, will seek to develop and commercialize technologies "to improve the success and increase the availability of organ transplantation." Under the terms of the agreement, Baxter will own 70% of Nextran, and Princeton, New Jersey-based DNX will hold 30% of the firm. Nextran will operate as an affiliate of Baxter.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.